Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Au­tho­ri­sa­tion Grant­ed for the Mon­o­clon­al An­ti­body Com­bi­na­tion Evusheld (Tix­agevimab and Cil­gav­imab) for COVID-19 Pre­ven­tion

The European Commission authorised the monoclonal antibody combination Evusheld (tixagevimab and cilgavimab) for the prophylaxis of COVID-19 disease on 25 March 2022, thereby following the recommendation for authorisation from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) dated 24 March 2022. The applicant for authorisation is the company AstraZeneca AB. The two antibodies contained in Evusheld are both SARS-CoV-2 neutralising antibodies.

Symbolic image Doctor forms an antibody model between his hands (Source:paulita/Shutterstock.com)

The Evusheld antibody cocktail is used to prevent COVID-19 in adults, adolescents, and children aged 12 years and older and weighing at least 40 kg. Evusheld should be administered under conditions that allow for treatment of severe hypersensitivity reactions, such as anaphylaxis. Individuals who have received Evusheld should be monitored after use in accordance with local medical practice.

Evusheld Available in Germany since February

The Federal Ministry of Health (BMG) began providing limited quotas of the drug Evusheld (tixagevimab/cilgavimab) for the prophylaxis of COVID-19 in mid-February 2022 for certain groups of people within the framework of the Supply Assurance for Medical Needs Ordinance (Medizinischer Bedarf Versorgungssicherstellungsverordnung, MedBVSV).

Updated: 25.03.2022